Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.62 |
| ▸ | KDM1A | O60341 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | F3 | P13726 | 1/20 | 0.62 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.62 |
| ▸ | NAMPT | P43490 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580183 | 0.87 | HDAC1 (0.58) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL5790114 | 0.84 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL3553337 | 0.83 | HDAC1 (0.57) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL2434821 | 0.83 | HDAC1 (0.78) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL1067366 | 0.83 | HDAC1 (0.65) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL3643968 | 0.82 | HDAC1 (0.76) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL18347845 | 0.80 | HDAC1 (0.76) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL8047689 | 0.80 | HDAC1 (0.76) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL28596954 | 0.80 | HDAC1 (0.72) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL7742679 | 0.79 | NAMPT (0.68) | HDAC1HDAC3HDAC2HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186885-A1 | FZD7 SPECIFIC ANTIBODIES AND VACCINES TO TREAT CANCER AND CONTROL STEM CELL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-07-05 | — | — | US | claimed |
| WO-2016205551-A2 | FZD7 SPECIFIC ANTIBODIES AND VACCINES TO TREAT CANCER AND CONTROL STEM CELL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-22 | — | — | WO | claimed |
| JP-2011506455-A | — | — | 2011-03-03 | — | — | JP | claimed |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2010-10-28 | — | — | US | claimed |
| EP-2231147-A2 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | Novartis AG (CH) | 2010-09-29 | — | — | EP | claimed |
| WO-2009076170-A2 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | claimed |
| US-20080200489-A1 | Combination of Organic Compounds | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | claimed |
| EP-1915154-A2 | COMBINATION OF ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-04-30 | — | — | EP | claimed |
| WO-2007022044-A2 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | claimed |
| US-12616733-B2 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12612644-B2 | Scalable method for recombinant AAV production | REGENXBIO INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260041767-A1 | METHODS OF IMPROVING CELLULAR THERAPY WITH ORGANELLE COMPLEXES | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2026-02-12 | — | — | US | disclosed |
| US-20250290915-A1 | METHOD FOR PREDICTING RESPONSIVENESS TO THERAPY | Cancertain Limited (GB) | 2025-09-18 | — | — | US | disclosed |
| US-12359208-B2 | Thermal control of T-cell immunotherapy through molecular and physical actuation | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2025-07-15 | — | — | US | disclosed |
| WO-2007080124-A1 | COMBINATION OF MTOR INHIBITOR AND ANTIPOLATE COMPOUND | NOVARTIS AG (CH) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007071443-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071442-A2 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071440-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007022044-A2 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006065780-A2 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041767-A1 | METHODS OF IMPROVING CELLULAR THERAPY WITH ORGANELLE COMPLEXES | TFAM, FIS1, TUFM | HDAC1 3196/4885HDAC3 2085/4885HDAC2 2933/4885 |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | ANXA5, BAX, ANXA6 | HDAC1 647/4885HDAC3 260/4885HDAC2 670/4885 |
| US-12616733-B2 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | XBP1, MCL1, CD81 | HDAC1 3927/4885HDAC3 4002/4885HDAC2 4367/4885 |
| US-20080200489-A1 | Combination of Organic Compounds | HDAC1, HDAC2, HDAC4 | HDAC1 1/4885HDAC3 5/4885HDAC2 2/4885 |
| US-12612644-B2 | Scalable method for recombinant AAV production | HDAC9, HDAC1, HDAC3 | HDAC1 2/4885HDAC3 3/4885HDAC2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.